Glycogen storage disease type VI: what to do when extended-release corn starch (Glycosade) fails to achieve blood glucose and ketone targets

In GSD type VI, dietary supplementation with extended-release corn starch (Glycosade) is used to prevent overnight hypoglycaemia. When this approach fails to keep blood glucose and ketone levels within target range, a next-step protocol applies.

Previous line — failure condition

The preceding treatment — extended-release corn starch from waxy maize (Glycosade), given orally in children over 5 years and adults — did not achieve its defined therapeutic goals:

Blood glucose 70–100 mg/dL not maintained
Blood ketones 0.0–0.2 mmol/L not maintained

Next-step approach (partial)

For patients with GSD type VI who have progressed to advanced liver disease, liver transplantation may be considered as a next-step intervention. Complete eligibility criteria, evaluation pathway, and the full management algorithm are available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1038/s41436-018-0364-2

As liver manifestations usually improve with conservative treatment, liver transplantation is rarely needed.

However, as there is a spectrum of clinical severity, with some patients having significant liver disease, and as we continue to learn more about the natural history of the disease, liver transplant may be indicated in cases with advanced liver disease.

View source ↗